The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight (Q38850561)

7 September 2017

1 reference

title

The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight (English)

1 reference

7 September 2017

Audrey Melvin

1

1 reference

7 September 2017

Carel W le Roux

series ordinal

2

1 reference

7 September 2017

Neil G Docherty

series ordinal

3

1 reference

7 September 2017

1 August 2016

1 reference

Current Atherosclerosis Reports

7 September 2017

1 reference

7 September 2017

18

1 reference

7 September 2017

49

1 reference

7 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-016-0599-9

7 September 2017

0 references

cites work

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

NPY and Y receptors: lessons from transgenic and knockout models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Brainstem nutrient sensing in the nucleus of the solitary tract inhibits feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

GOAT: the master switch for the ghrelin system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Expression of ghrelin receptor mRNA in the rat and the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Isolation and primary structure of human peptide YY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Effect of macronutrient composition on postprandial peptide YY levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Characterization of blood-brain barrier permeability to PYY3-36 in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

PYY3-36 and pancreatic polypeptide reduce food intake in an additive manner via distinct hypothalamic dependent pathways in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Long-term persistence of hormonal adaptations to weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Laparoscopic gastric bypass: development of technique, respiratory function, and long-term outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The effect of bariatric surgery on intestinal absorption and transit time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Roux-en-Y Gastric Bypass Surgery Increases Respiratory Quotient and Energy Expenditure during Food Intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Identification of membrane-type receptor for bile acids (M-BAR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Impact of Duodenal-Jejunal Exclusion on Satiety Hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0599-9

Distribution and Immunocytochemical Colocalization of Peptide YY and Enteroglucagon in Endocrine Cells of the Rabbit Colon*

21 January 2018

1 reference

12 December 2020

Glucagon-37 (oxyntomodulin) and glucagon-29 (pancreatic glucagon) in human bowel: analysis by HPLC and radioreceptorassay

1 reference

12 December 2020

Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons.

1 reference

12 December 2020

Central nervous system control of food intake

1 reference

12 December 2020

Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36

1 reference

12 December 2020

Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat

1 reference

12 December 2020

Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans

1 reference

12 December 2020

Laparoscopic sleeve gastrectomy as an initial bariatric operation for high-risk patients: initial results in 10 patients

1 reference

12 December 2020

Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2

1 reference

12 December 2020

A novel endoscopic delivery system for placement of a duodenal-jejunal implant for the treatment of obesity and type 2 diabetes.

1 reference

12 December 2020

Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans

1 reference

12 December 2020

Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy

1 reference

12 December 2020

Ghrelin enhances appetite and increases food intake in humans

1 reference

12 December 2020

Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet

1 reference

12 December 2020

PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats.

1 reference

12 December 2020

Oxyntomodulin inhibits food intake in the rat

1 reference

12 December 2020

Complete sequences of glucagon-like peptide-1 from human and pig small intestine

1 reference

12 December 2020

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

1 reference

12 December 2020

Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat

1 reference

12 December 2020

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-cont

1 reference

12 December 2020

Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.

1 reference

12 December 2020

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1 reference

12 December 2020

[Proteolytic processing by dipeptidyl aminopeptidase IV generates receptor selectivity for peptide YY (PYY)]

1 reference

12 December 2020

10.1007/S11883-016-0599-9

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference